|Bid||321.00 x 800|
|Ask||317.86 x 800|
|Day's Range||308.12 - 321.94|
|52 Week Range||259.02 - 460.21|
|Beta (5Y Monthly)||1.17|
|PE Ratio (TTM)||41.67|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Charles River (CRL) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Investors are optimistic about Charles River (CRL) on acquisitions of Cognate BioServices and Vigene Biosciences.
How far off is Charles River Laboratories International, Inc. ( NYSE:CRL ) from its intrinsic value? Using the most...